Abhyankar Surabhi D, Little Karis, Stitt Alan, Bhatwadekar Ashay D
Department of Ophthalmology, Eugene and Marilyn Glick Eye Institute, Indiana University School of Medicine, Indianapolis, IN, USA.
Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis, IN, USA.
J Alzheimers Dis Rep. 2025 Aug 10;9:25424823251361937. doi: 10.1177/25424823251361937. eCollection 2025 Jan-Dec.
Alzheimer's disease (AD) is a neurodegenerative condition manifesting as cognitive decline, memory deterioration, and behavioral alterations. Late-onset AD accounts for most diagnosed cases, with the onset of symptoms usually occurring after 65 years. At present, there are no proven treatments that alter the course of AD. For early detection and intervention, it is crucial to understand the underlying mechanisms and identify promising biomarkers for AD. Research suggests that the pathological processes of AD initiate years before the emergence of noticeable symptoms, which makes the early diagnosis more challenging. While various biomarkers, such as cognitive tests, imaging, and biological markers in blood and cerebrospinal fluid, have been proposed for early detection, their reliability, as matched with symptomatic stages, varies significantly. As a component of the central nervous system, the retina has attracted attention as a potential site for studying AD-related changes. Studies from human and animal models have revealed structural, vascular, functional, and metabolic changes in the retina through the early phases of AD. Furthermore, advances in ophthalmic technologies have facilitated the identification and characterization of AD-related changes such as amyloid-β and tau-protein deposition. This review provides an overview and perspective on AD as they relate to the retina and highlights the importance of ocular changes as surrogates for understanding and diagnosing AD.
阿尔茨海默病(AD)是一种神经退行性疾病,表现为认知能力下降、记忆力减退和行为改变。晚发型AD占大多数确诊病例,症状通常在65岁以后出现。目前,尚无经证实的可改变AD病程的治疗方法。为了早期检测和干预,了解其潜在机制并识别有前景的AD生物标志物至关重要。研究表明,AD的病理过程在明显症状出现前数年就已开始,这使得早期诊断更具挑战性。虽然已提出多种生物标志物用于早期检测,如认知测试、影像学检查以及血液和脑脊液中的生物标志物,但它们与症状阶段的匹配可靠性差异很大。作为中枢神经系统的一个组成部分,视网膜作为研究AD相关变化的潜在部位已引起关注。来自人类和动物模型的研究揭示了在AD早期阶段视网膜的结构、血管、功能和代谢变化。此外,眼科技术的进步有助于识别和表征与AD相关的变化,如淀粉样β蛋白和tau蛋白沉积。本综述概述了AD与视网膜的关系并提出观点,强调了眼部变化作为理解和诊断AD替代指标的重要性。